Cardiovascular Diseases

Obicetrapib Effective and Safe in Improving Lipids

Two randomized, controlled trials evaluated the efficacy and safety of obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor, in lowering low-density lipoprotein (LDL) cholesterol in patients at high risk for atherosclerotic cardiovascular disease (ASCVD).

  • The first multinational trial investigated obicetrapib monotherapy (10 mg daily) in 2530 high-risk patients already on maximum tolerated lipid-lowering therapy. Over 84 days, obicetrapib reduced LDL-C by 29.9% compared to placebo, with a between-group difference of −32.6%. Additional improvements included an 18.9% reduction in apolipoprotein B, a 29.4% reduction in non-HDL cholesterol, and a 33.5% reduction in lipoprotein(a), as well as a 136.3% increase of HDL cholesterol.  Adverse event rates were similar between the treatment and placebo groups.
  • The second US trial evaluated a fixed-dose combination (FDC) of obicetrapib (10 mg) and ezetimibe (10 mg) in 407 patients with pre-existing or high risk for ASCVD. Over the same 84-day period, the FDC led to a 48.6% reduction in LDL-C versus placebo, outperforming both obicetrapib (31.9%) and ezetimibe (separately) in monotherapy arms. Safety outcomes, including adverse and serious adverse event rates, were comparable across treatment groups and consistent with prior data.

Both trials show that obicetrapib is effective in reducing LDL cholesterol, with enhanced efficacy when combined with ezetimibe. The FDC offers a potent oral treatment option for high-risk patients who need additional LDL-C lowering beyond standard therapy. These findings suggest that obicetrapib may be a useful adjunct to lipid lowering in high risk patients, and a cardiovascular outcomes trial is underway. Source: https://www.nejm.org/; https://www.thelancet.com/

hyangiu

Recent Posts

Hyperlipidemias and Inflammation Independently and Synergistically Raise CVD Risk

A UK longitudinal associations study revealed that hyperlipidemias and inflammation independently and together raise the…

3 days ago

Ultraprocessed Food Consumption and Early Death

A study shows that eating a lot of highly processed foods is likely causing a…

1 week ago

Dose Response of Physical Activity in CVD and Mortality

Two recent studies highlight the importance of physical activity volume and intensity in reducing cardiovascular…

2 weeks ago

Faster Walking Pace May Reduce Risk of Cardiac Arrhythmias

A prospective UK cohort study found that both self-reported average or brisk walking pace and…

2 weeks ago

4:3 Intermittent Fasting Outperforms Daily Caloric Restriction for Weight Loss

A U.S. randomized clinical trial found that 4:3 intermittent fasting (IMF) led to slightly greater…

1 month ago

Comparative CVD Efficacy of Newer Glucose-Lowering Drugs in Elderly T2D Patients

A Danish nationwide cohort study provided real world evidence that both glucagon-like peptide 1 receptor…

1 month ago

This website uses cookies.